Go
View All
Akathisia
Algorithm for treating catatonic stupor.
Antipsychotic withdrawal symptoms.
Blood levels following discontinuation of treatment with 25mg every 2 weeks: last injection at week 4.
Classification of renal impairment.
Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar).
Common withdrawal symptoms with SSRIs and similar drugs.
Drug treatment for depression.
First-Episode Schizophrenia
Flowchart for naloxone administration.
Flow chart for the use of covert medication.
General Guidelines
Linear dose reductions of olanzapine cause increasingly large reductions in D2 dopaminergic receptor blockade.
Linear reductions of dose cause increasingly large reductions in effect on GABA-A receptor occupancy.
Linear reductions of dose cause increasingly large reductions in effect on receptor targets, probably associated with more withdrawal effects.
Management of antipsychotic-induced hyperprolactinaemia.
Metabolism of alcohol.
Relapse or Acute Exacerbation of Schizophrenia
Suggested guidelines for managing cardiovascular risk prior to and during treatment with acetylcholinesterase inhibitors (AChE-Is) in Alzheimer's disease.
Summary of recommendations for the treatment of tics and Tourette's syndrome.
Summary of recommendations in the treatment of insomnia.
The pharmacological management of premenstrual dysphoric disorder.
The risk of recurrence in patients who have several episodes of depression.
The use of lithium with clozapine.
Treatment of acute mania or hypomania.
Treatment options for children and young people with obsessive compulsive disorder.
Displaying items 1 - 26 of 26